The European Commission has opened an in-depth investigation into Carcassone airport’s funding arrangements with France and marketing agreements between the airport and Ryanair. Carcassonne is owned by the Languedoc-Roussillon region. Until May 2011, the airport was operated by the local Chamber of Commerce; it is now operated by Veolia Transport.
The Commission is concerned with public subsidies awarded to the Chamber of Commerce between 2000 and 2010. The subsidies went toward airport infrastructure and amounted to at least 11 million euros. The Commission is also looking into 8 million euros in support measures for the Chamber of Commerce’s operating costs. The public subsidies and support measures may have violated EU state aid rules. Measures granted to Veolia Transport and Languedoc-Roussillon’s financing will be examined as well.
Moreover, the Commission is to determine if airport operators and Ryannair’s agreements were made on market terms.
Full content: EC Press Release
Related content: The Current Financial Crisis and State Aid in the European Union: Has It Been Timely and Appropriate? (Abel Mateus, University College London)
Featured News
Federal Judge Signals Revisions Likely in DOJ Case Targeting Live Nation
Jan 22, 2025 by
CPI
American Airlines and JetBlue Agree to $2 Million Legal Fee Settlement with U.S. States
Jan 22, 2025 by
CPI
Federal Judge Dismisses Class Action Alleging Inflated Yacht Commission Fees
Jan 22, 2025 by
CPI
Doug Gurr Appointed Interim Chairman of UK’s Competition Authority
Jan 22, 2025 by
CPI
LinkedIn Faces Lawsuit Over Alleged Misuse of Customer Data for AI Training
Jan 22, 2025 by
Amanda Adams
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan